Investors of Vistagen Therapeutics Urged to Join Class Action Amid Major Losses

Vistagen Therapeutics Class Action Notice

In a recent announcement, the Gross Law Firm has called on shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) who faced financial losses to consider joining a class action lawsuit. This notice aims to assist investors who purchased shares of the company during a specific period, from April 1, 2024, to December 16, 2025.

Background of the Case

The class action lawsuit is based on allegations that Vistagen’s executives made misleading and positive statements regarding their Phase 3 PALISADE-3 trial for fasedienol, a drug developed for treating social anxiety disorder. Investors were given the impression of a successful outcome, but on December 17, 2025, Vistagen admitted that the trial results did not show a statistically significant improvement on the primary endpoint, leading to a devastating reduction in the company's stock price.

The share price plummeted from $4.36 per share to just $0.86, representing an alarming loss of over 80%. Such significant drops highlight the critical nature of the misleading statements made by the company, which ultimately affected the shareholders' investments.

Class Action Participation

The Gross Law Firm is actively seeking shareholders who were impacted by this situation. Interested parties are encouraged to register for the class action lawsuit by visiting the firm’s website. Even those who do not wish to be a lead plaintiff may still participate in the recovery process as part of the class. The deadline for registration to possibly become a lead plaintiff is set for March 16, 2026.

Once registered, shareholders will gain access to monitoring software that provides updates on the progress of the case. Importantly, there are no costs or obligations for shareholders who join the lawsuit.

Importance of the Case

The Gross Law Firm emphasizes the necessity for businesses to uphold ethical standards and to communicate transparently with their investors. The firm is dedicated to holding companies accountable for any deceptive practices that can lead to financial harm for stakeholders. Their mission is to recover losses suffered by investors, strengthening the accountability framework in the corporate world.

Next Steps

To join the class action, shareholders must submit their information through the provided links by the specified deadline. The Gross Law Firm is known for its dedication to protecting investors' rights and its efforts to ensure transparent business practices in the market. Those interested should not wait, as the opportunity to join this action is time-sensitive.

For further inquiries or to register, interested shareholders can directly contact the Gross Law Firm’s office at their New York location or through their official website. Taking action promptly can provide investors a chance to recover from their substantial losses effectively.

Contact Information
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

Stay informed, protect your investments, and consider participating in this class action against Vistagen Therapeutics to seek justice for financial losses incurred during the misleading pursuit of their business objectives.